Fig. 2: JQ-1 reduces ROS and lipid peroxidation in H9C2 cardiomyocytes after erastin treatment. | Cell Death & Disease

Fig. 2: JQ-1 reduces ROS and lipid peroxidation in H9C2 cardiomyocytes after erastin treatment.

From: (+)-JQ-1 alleviates cardiac injury in myocardial infarction by inhibiting ferroptosis through the NAMPT/SIRT1 pathway

Fig. 2

A Representative DCFH-DA fluorescence (ROS probe) images in H9C2 cardiomyocytes treated with JQ-1 under the erastin challenge. Scale bars, 100 µm. B Quantitative analysis of ROS levels in H9C2 cardiomyocytes (n = 3). C Representative flow cytometric plots of H9C2 cardiomyocytes treated with JQ-1 under the erastin challenge. D Quantitative analysis of intracellular ROS levels in H9C2 cardiomyocytes (n = 3). E Representative lipid peroxidation staining images in H9C2 cardiomyocytes treated with JQ-1 under the erastin challenge. Red: unoxidized C11-BODIPY; Green: oxidized C11-BODIPY; Blue: Hoechst-stained nucleus. Scale bars, 50 μm. F Quantitative analysis of lipid peroxidation levels in (E) (n = 3). Quantitative analysis of MDA levels (G) and GSH/GSSG levels (H) in H9C2 cardiomyocytes treated with JQ-1 under the erastin challenge (n = 3). The data are presented as mean ± SEM. The statistical significance of the data was evaluated using a two-way ANOVA followed by Tukey’s test for multiple comparisons (B, D, F–H). **P < 0.01.

Back to article page